Ocuphire Pharma Investor Day Presentation Deck
8
Ocuphire Pipeline & Clinical Milestones
Multiple Phase 3 & Phase 2 Clinical Data Readouts Anticipated Over the Next Year
Product
Candidate
0.75% NyxolⓇ
Eye Drop
0.75% NyxolⓇ+
Low-Dose 0.4%
Pilocarpine
Eye Drops
0.75% NyxolⓇ
Eye Drop
APX3330
Oral Pill
Indication
APX2009
(Intravitreal or
Reversal of Mydriasis
(RM)
Presbyopia (P)
Dim Light or Night
Vision Disturbances
(NVD)
Diabetic Retinopathy
(DR)/ Macular Edema
(DME)
DME or Wet Age-
Related Macular
Local Delivery) Degeneration (wAMD)
Pre-clinical Phase 1
Phase 2
Phase 3
Regulatory
Approval
Anticipated Milestones
MIRA-3 Phase 3 data
expected in early 2022 (n=330)
MIRA-4 Pediatric safety study
data expected in early 2022
(n=20)
OVEGA Phase 3 program
planned to initiate in mid 2022
OLYNX-1 Phase 3 data
expected in early 2022 (n=140)
OZETA-1 Phase 2b data
expected in 2H22 (n=90-100)
Seeking partner funding for
IND enabling studies and
further development
Positive data readout
Ongoing trial
Note: 0.75% Nyxol (Phentolamine Ophthalmic Solution) is the same as 1% Nyxol (Phentolamine Mesylate Ophthalmic Solution)
Ocuphire
PHARMAView entire presentation